Interactive AGM Yes/No vote, page-40

First 40 Last

Share
Profile

Follow
adreamer

1,858 Posts.

2264

15/02/23

18:26

Post #: 66270551
Share

Originally posted by 10xhunting: ↑

@kpax. Ref being able to join the AGM via Zoom link. Obviously yes is the only answer. Most surprised there is even a need for this question ?
In doing some DD note this did not occur last meeting but then a video was published ?? Still very keen on PAA however would like to see a bit more liquidity before jumping in. One or two solid announcements should fix that.
Conversation among the contributors generally one of the more supporting and civil ones I follow on HC.
I still have one aspect I find a little confusing. Have been back through many of the announcements and note that management state Elanco own the patent to the base compound for animals and then tend to follow this up with that PAA / Pitney hold various patents for human use. It just does not set out whether or not the Elanco patents also cover human use. Note management has also referred gaining a lic for use from Elanco. Surely even if their patent does cover human use, Elanco being only animal focused would surely be happy to do a commercial deal to allow PAA to take the human side to market. What company (even big pharma) would want to have their name attached to preventing a treatment for MND or Covid. Am I being naive ?

Expand

Patents for Elanco cover the base compound and use as a a drench plus a few other things.
That is about it.
Any IP that has been developed as part of the projects run by PharmAust reside with PharmAust (even when shared information with ELanco)
Any of the IP bought by PAA resides with PAA and they have purchased a number of patents over time.

So to go commercial before the composition of matter patent expires:
PharmAust needs a commercial arrangement for the period of remaining time to use the Monepantel base matter.

Elanco do not have patents for the human side at all, and not even for MPL in vet use for cancer.
They only have the composition of matter that has influence over PharmAust. And this only becomes important when it is becoming for sale in the pharmacies in various countries. We are a ways off that as while in trial mode, the patients are not paying.

Cheers

Last edited by adreamer: 15/02/23

PAA Price at posting: 8.9¢ Sentiment: Buy Disclosure: Held
5 Upvote

1 Great analysis

Reply

Top Stories

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

What's causing the cost-of-living crisis, and how to navigate it

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war